Teva Pharmaceutical Industries Limited
TEVJF
$28.36
-$4.48-13.64%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.32% | 0.02% | 2.07% | 3.82% | 4.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.32% | 0.02% | 2.07% | 3.82% | 4.40% |
| Cost of Revenue | -1.89% | -0.46% | 1.85% | 3.38% | 3.40% |
| Gross Profit | 10.84% | 0.51% | 2.31% | 4.29% | 5.48% |
| SG&A Expenses | 7.30% | 4.16% | 5.12% | 5.42% | 5.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 90.91% | 5.00% | 27.27% | 166.67% | -191.67% |
| Total Operating Expenses | 1.03% | 1.00% | 2.54% | 4.18% | 3.97% |
| Operating Income | 17.12% | -3.40% | 0.37% | 2.48% | 6.13% |
| Income Before Tax | 196.26% | 269.94% | 51.05% | 36.78% | -106.43% |
| Income Tax Expenses | -126.67% | -65.41% | -84.68% | 2,153.85% | 11,350.00% |
| Earnings from Continuing Operations | 172.28% | 154.31% | 78.27% | -68.80% | -218.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -102.19% | -80.23% | -98.32% | -88.78% | 471.43% |
| Net Income | 185.97% | 174.24% | 65.12% | -168.48% | -192.68% |
| EBIT | 17.12% | -3.40% | 0.37% | 2.48% | 6.13% |
| EBITDA | 11.79% | -3.55% | -0.96% | -0.16% | 2.33% |
| EPS Basic | 184.91% | 173.52% | 63.80% | -165.52% | -188.79% |
| Normalized Basic EPS | 2.51% | -13.18% | -14.64% | -10.10% | 30.02% |
| EPS Diluted | 182.36% | 169.57% | 60.64% | -161.53% | -181.76% |
| Normalized Diluted EPS | 0.80% | -13.69% | -14.62% | -9.76% | 31.18% |
| Average Basic Shares Outstanding | 1.30% | 1.22% | 1.18% | 1.16% | 1.01% |
| Average Diluted Shares Outstanding | 2.99% | 2.01% | 1.28% | 0.95% | 0.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |